In obese adults with HFpEF, GLP-1 receptor agonists may reduce the risk of developing atrial fibrillation by about 20%, but one drug (tirzepatide) showed a higher rate than placebo, indicating the effect may vary by drug and involve complex changes in heart rhythm.
Claim Context
GLP-1 receptor agonists are associated with a reduction in new-onset atrial fibrillation by approximately 20% in obese adults with heart failure with preserved ejection fraction, though this effect is inconsistent across agents, with tirzepatide showing numerically higher rates than placebo, suggesting complex atrial electrophysiological modulation.
“In a large propensity-matched cohort, GLP-1RA use was associated with a 20% relative risk reduction of new-onset AF or atrial flutter. Randomized data from STEP-HFpEF also demonstrated lower incident AF with semaglutide (1.1% versus 3.4%; P<0.001)... In contrast to GLP-1RA only studies, the SUMMIT trial observed numerically higher rates of new onset AF with active treatment compared with placebo (6.3% versus 3.3%).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether GLP-1 receptor agonists as a class reduce new-onset atrial fibrillation in HFpEF patients, and whether this effect differs between semaglutide, tirzepatide, and other agents.
A systematic review and meta-analysis of at least 15 RCTs involving 20,000+ HFpEF patients comparing semaglutide, tirzepatide, liraglutide, and placebo, with adjudicated AF events as primary endpoint, stratified by agent and baseline AF risk.
Whether semaglutide reduces new-onset AF compared to tirzepatide in HFpEF patients, independent of weight loss and BP change.
A double-blind RCT of 3,000 HFpEF patients randomized 1:1 to semaglutide 2.4 mg/week or tirzepatide 15 mg/week for 104 weeks, with continuous ECG monitoring; primary outcome: time to first AF episode, adjusted for weight change, BP, and renal function.
Whether the degree of LA volume reduction with GLP-1RAs predicts incident AF in HFpEF patients.
A prospective cohort study of 2,500 HFpEF patients initiating GLP-1RA therapy, measuring LA volume by CMR at baseline and 24 weeks, and tracking AF incidence over 5 years, adjusting for weight loss, BP, and NT-proBNP.
Whether baseline atrial fibrosis on CMR correlates with GLP-1RA-induced changes in AF incidence.
A cross-sectional analysis of 200 HFpEF patients on GLP-1RAs, measuring atrial fibrosis via late gadolinium enhancement CMR and correlating it with incident AF history and drug type.
Whether individual patients develop AF shortly after starting GLP-1RAs despite weight loss.
A case series of 20 HFpEF patients who developed new-onset AF within 6 months of starting GLP-1RA therapy, documenting detailed cardiac imaging, biomarkers, and drug exposure history.